UK advanced therapy trials continue strong growth in 2025

The UK maintained a strong position in advanced therapy clinical trials in 2025, with 193 ongoing trials recorded in the Cell and Gene Therapy Catapult’s (CGT Catapult) UK ATMP Clinical Trials Database. Early-stage trials remain high, making up 56% of the total, while 80% of trials were commercially sponsored.

The UK accounted for 9% of all global ATMP trials and 57% of European trials, reflecting its competitive edge in this rapidly growing sector. Gene therapies dominate the landscape, representing over 80% of trials, split evenly between ex vivo and in vivo approaches. Oncology remains the leading focus, with 35% of trials in this area, alongside growing activity in inflammation and immune system therapies.

Matthew Durdy, CEO of CGT Catapult, said: “With a supportive regulator and recent updates such as the increase to the NICE thresholds, the UK is well-positioned to benefit from the health and economic impacts of advanced therapy clinical trials. These studies are essential for building the skills, infrastructure, and clinical environment needed to deliver innovative therapies safely and efficiently.”

The data highlights the UK’s ongoing commitment to pioneering research in cell and gene therapies, positioning it for continued growth as these treatments move toward broader clinical adoption.

More information online